RI
CLSD

RTW Investments’s Clearside Biomedical CLSD Stock Holding History

RTW Investments’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-253,735
Closed -$10.5M – 111
2021
Q4 		$10.5M Sell
253,735
-26,716
-10% -$1.73M 0.15% 80
2021
Q3 		$25.2M Hold
280,451
– – 0.38% 55
2021
Q2 		$20.5M Hold
280,451
– – 0.31% 57
2021
Q1 		$10.4M Buy
280,451
+16,576
+6% +$832K 0.16% 69
2020
Q4 		$10.8M Buy
263,875
+707
+0.3% +$18.3K 0.18% 66
2020
Q3 		$6.08M Buy
263,168
+1,993
+0.8% +$51.5K 0.15% 76
2020
Q2 		$7.37M Buy
261,175
+2,276
+0.9% +$67K 0.21% 57
2020
Q1 		$6.6M Buy
258,899
+8,892
+4% +$329K 0.28% 51
2019
Q4 		$10.9M Buy
250,007
+160
+0.1% +$3.36K 0.41% 46
2019
Q3 		$2.36M Buy
+249,847
New +$3.58M 0.14% 54

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments's CLSD Position: Q1 2022 in Review

RTW Investments sold out of Clearside Biomedical (CLSD) in Q1 2022, closing a stake of 253,735 shares — an estimated $10.5M sold.

RTW Investments first reported a position in CLSD in Q3 2019 and held it in 10 quarters. The position peaked at $25.2M in Q3 2021. 60 funds tracked by Wall St. Rank hold CLSD as of Q1 2022.

  • RTW Investments reported no remaining Clearside Biomedical position as of Q1 2022 after selling out during the quarter.
  • RTW Investments sold 253,735 Clearside Biomedical shares in Q1 2022, an estimated $10.5M.
  • RTW Investments first reported a position in Clearside Biomedical in Q3 2019 and held it in 10 quarters.
  • RTW Investments's Clearside Biomedical position peaked at $25.2M in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2022.

Based on RTW Investments's 13F filing for Q1 2022, filed 16 May 2022.